Corporate Information Archives - Page 21 of 33

ZICCUM’S NEW DEVELOPMENT DIRECTOR ON A PIVOTAL PHASE FOR THE COMPANY

With a range of research collaboration projects ongoing at its lab in Lund, all running in parallel with continuing work on developing LaminarPace for GMP industrial production, Ziccum’s new Development Director Anna Lönn faces a demanding schedule. With previous senior posts at Tetra Pak, Galencia and Bioinvent she discusses the new phase in Ziccum’s development, and why she chose to leave a global manufacturing giant to join a small startup with a big idea.

“Ziccum made great steps forward last year and is now moving into a pivotal new phase requiring new structures,” says Anna Lönn. “Every day now we’re gathering more and more knowledge about the machine, the process and products. This knowledge will be crucial in demonstrating to a bigger partner like a large-scale vaccine manufacturer ‘this is what we can do, this is where we are, now let’s take the next step together’, so we need to systematically harness and structure that knowledge across every process we work on.”

Parallel projects
In a busy and critical research period Ziccum currently has a range of research collaborations running in parallel at its lab – from big pharma projects testing dry vaccine formulations to public research bodies testing subunit vaccines and adjuvants. In parallel with these projects Ziccum continues to develop its LaminarPace (LAPA) ambient air-drying system, measuring and setting parameters and heading towards meeting the regulatory quality requirements ultimately needed for GMP approval for industrial manufacture and installation in its own small-scale Fill and Finish plant.

“It’s hectic” says Lönn, “we’re a small, highly skilled, team working on multiple projects, but they’re all totally hand-in-hand and they all feed in and build new knowledge back into the LAPA development in every project, strengthening our case, delivering new data and reducing risk from a partner perspective – making us not just a ‘nice-to-have’ partner but a ‘need-to-have’ one.”

From global giant to startup
Anna Lönn has extensive experience from product and pharmaceutical development and manufacturing. Her most recent role was as a Project Manager at Tetra Pak Processing Systems. “At Tetra Pak I worked in research and technology, developing novel processing machines and techniques, including projects with small innovative startups. At Tetra Pak I was also the driver for a new innovation and focus area, working in an agile framework to secure progress within this unknown area. In 16 years at Bioinvent I worked with process development, scale up and cGMP manufacturing of antibodies for clinical trial studies. As CMC Project Manager at Galencia I managed in-house and customer development and cGMP manufacturing projects. So, my skillset related really well to Ziccum.”

Leaving a global giant like Tetra Pak for a small startup like Ziccum is still a bold step though. What inspired her? “The concept of dry vaccines is really inspiring to me. From a science, sustainability and global healthcare perspective it will be a huge game changer. I’ve always been engaged with sciences that drive sustainability, for example my technical licentiate thesis was on biofuel.

“I believe that I will bring in the experience and knowledge related to processes and product development from both large and mid-size companies to Ziccum, who is now taking the next step – moving from a more explorative development phase to a more structured process development stage. My driving force is that I really want to be a part of this groundbreaking technology with the aim of contributing to a better world. I want to know that I’m having a real impact on the company I’m with, at Ziccum the strategic big-picture processes I work with are absolutely crucial in its current phase of development, so I’m very excited to contribute to such an exciting company and technology.”

ZICCUM’S NEW DEVELOPMENT DIRECTOR ON A PIVOTAL PHASE FOR THE COMPANY

Anna Lönn

Ziccum AB (publ) releases Q2 Report 2021

(Lund, Sweden, 26 August 2021) Ziccum AB today releases its Q2 Report for 2021. For the first time the Report will also be released in a digital online format allowing subscribers and readers to more easily interact with and navigate every aspect of the Report.

Read the Q2 Report in its new digital format here: https://reports.ziccum.com/delarsrapport-q2-2021/start/

The PDF of the Report is attached to this Press Release, and is available on the company’s website on: https://ziccum.com/investors/financial-reports/

Ziccum Q2 2021

Ziccum AB (publ) publicerar delårsrapport för andra kvartalet 2021

(Lund, Sverige, 26 augusti 2021) Ziccum AB meddelar att bolagets Q2-rapport för 2021 nu är tillgänglig. För första gången kommer rapporten också att släppas i ett digitalt onlineformat som gör det enklare att navigera och ta del av rapporten.

Läs Q2-rapporten i sitt nya digitala format här: https://reports.ziccum.com/delarsrapport-q2-2021/start/

PDF-fil bifogas på detta pressmeddelande, och finns på företagets webbplats på: https://ziccum.com/investors/financial-reports/

Ziccum Q2 2021

ZICCUM AB: Andreas Pettersson, Senior Director of Corporate Finance at Northvolt, on being Ziccum’s new Board member

As Senior Director of Corporate Finance at Northvolt AB, a leading innovator in sustainable lithium ion battery production, Andreas Pettersson, Ziccum’s new Board member, is no stranger to disruptive technologies: “Disruption always meet resistance at first, but no incumbent is bigger than history – or global megatrends. Right now, we’re seeing serious and substantial investment in technologies that can genuinely drive sustainable development.”

What first drew you to Ziccum?
I thought Ziccum was an attractive equity story. It has a strong societal mission – backed up by proven, powerful megatrends. From the IMF to the WTO to the World Bank and more – we’re seeing enormous urgency and willingness to invest in solving the global vaccine supply problem now, in both developing and developed countries. Given the amount of vaccine wastage the current Cold Chain contributes to, and the strong likelihood of further pandemics, governments, developments banks, NGOs and INGOs are all re-examining today’s vaccine supply chains – and whether they are really fit for purpose. I believe thermostable vaccines will, and must, happen. The need for a solution to global vaccine supply is immense – the current supply structures alone don’t seem able to fully meet the need.

What convinces you that LaminarPace can be the solution?
LaminarPace’s ambient air-drying technique is a proven, well-functioning technology that can be scaled. And when it comes to scaling execution is key especially when you’re developing a disruptive technology as you will face resistance. So, you need the right team with the right drive and values. The Ziccum team is passionate and determined.

Do you recognize similarities between Ziccum and Northvolt?
Yes, there are some clear resemblances! Even before Covid19 the WHO estimated that up to 50% of vaccines were wasted globally every year because of temperature control and supply chain issues, which simply isn’t acceptable or sustainable. So firstly there is the scale and urgency of the societal problem. I also see growing regulatory and governmental interest in solving the problem, as with Northvolt. There’s the fact that Ziccum is a disruptive technology in a marketplace largely controlled by a few incumbent OEMs – so materially impacting the supply chain and with that the profit pool in the value chain will meet resistance. But again, we come back to the scale of the need and megatrends. New models are needed and will be adopted.

Right now, the technology change in the supply chains and Ziccum are in an early phase, but as awareness develops you could see a rapid acceleration, like you are seeing in the electrical vehicle space for Northvolt. Only a few years ago the electrification of the car industry was an early interesting idea, but then as the snowball kept rolling and market adoption accelerated, everyone now agrees that this is happening and the car manufactures, regulators and investors are putting significant resources into being at the forefront of that development. With disruptive technologies you can reach a tipping point quite suddenly, when things start moving really fast. The question is – when will it come?

Like Ziccum, Northvolt stresses the role its technology can play in reaching the UN’s Sustainable Development Goals (SDGs). Do you think the market see SDGs differently now?
Absolutely. Even five years ago SDGs were tucked away on the back pages of an Annual Report as part of a small CSR section but now it is a very critical part of many companies’ DNA. That’s an enormous change. I know it’s the same with Ziccum. We also find doors opening to us exactly because sustainability is such a core value for us. Right now the market is being really proactive, and actively looking for technologies that can genuinely drive sustainability and sustainable development, and we know vaccines and vaccine access are key metrics in sustainable development – so here too Ziccum’s offering has great potential.

What will your particular skillset contribute to Ziccum?
Through my four years at Goldman Sachs in London and nine years at EQT in Stockholm in the buyout industry, I think I can add a lot from an investor perspective I also think I can bring a broad palette of commercial, strategic and investment perspectives and can help the company focus on the right things. Right now, I’m really looking forward to working closer to the Ziccum team on this journey.

ZICCUM AB: Andreas Pettersson, Senior Director of Corporate Finance at Northvolt, on being Ziccum's new Board member

1564926435350

Optionsinnehavare i Ziccum utnyttjar samtliga teckningsoptioner i incitamentsprogrammet 2018/2021

Den 25 april 2018 beslutade årsstämman i Ziccum AB (publ) (”Ziccum” eller ”Bolaget”) att emittera 200 000 teckningsoptioner till styrelsens fyra ledamöter inom ramen för ett teckningsoptionsprogram (”LTI 2018/2021”). Ziccum meddelar idag att samtliga teckningsoptioner i LTI 2018/2021 utnyttjats för teckning av nya aktier i Bolaget. För att finansiera aktieteckningen har optionsinnehavarna sålt 120 000 teckningsoptioner till en enskild långsiktig investerare, som nu också utnyttjat dessa teckningsoptioner.

Ziccum meddelar idag att LTI 2018/2021 som riktades till Ziccums styrelseledamöter och som omfattar 200 000 teckningsoptioner, med utnyttjandeperiod under perioden 26 april – 26 maj 2021, har avslutats och att samtliga teckningsoptioner utnyttjats. Lösenpriset uppgick till 11 kronor per aktie, innebärande att Ziccum, genom aktieteckningen, tillförs 2,2 miljoner kronor.

För att finansiera aktieteckningen har optionsinnehavarna i lika delar överlåtit sammanlagt 120 000 teckningsoptioner till en enskild långsiktig investerare. Även dessa överlåtna teckningsoptioner har utnyttjats.

Genom utnyttjandet kommer antalet aktier och röster i Bolaget att öka med 200 000 och antalet aktier i Bolaget kommer därmed uppgå till 9 806 200.

Optionsinnehavare i Ziccum utnyttjar samtliga teckningsoptioner i incitamentsprogrammet 2018/2021

ZICCUM AB welcomes urgent calls to ramp up vaccine manufacturing across the globe to address inequity in vaccine access and prevent future pandemics

Last week saw repeated calls from influential global stakeholders to establish or upgrade vaccine manufacturing facilities, particularly those in low- and middle- income countries (LMICs). Ziccum CEO: “We welcome these important developments and share the commitment to scale up vaccine manufacturing and improve Fill and Finish capacity globally. These urgent calls, from multiple groups, show that increasing regional vaccine manufacture is now a question of when, not if. Let’s act now – together.”

Major announcements and reports emphasizing regional manufacture:

The Coalition for Epidemic Preparedness Innovations (CEPI) announced the formation of the COVAX Manufacturing Task Force – an initiative that will be spearheaded by the co-leads of COVAX to urgently address the shortages in vaccine production through improvements in vaccine manufacturing infrastructure.
The Independent Panel for Pandemic Preparedness and Response presented a report that called for urgent action to prevent future pandemics, boosting vaccine production takes time so enabling it must begin now.
The Partnership for Evidence-Based COVID-19 Response (PERC) published a report on the COVID-19 response in Africa, highlighting the urgent need to facilitate local vaccine manufacturing in the African region.

The COVAX Manufacturing Task Force, announced by CEPI has laid out a 3-stage plan to enhance existing vaccine production capacity, as well as expanding long-term production. The Task Force aims to address immediate manufacturing bottlenecks by increasing existing capacity and overcoming workforce limitations, through identifying and matching “Fill and Finish” manufacturers with producers of active ingredients, accelerating approvals of exports permits/ customs clearances and facilitating partnerships for supply of vital vaccine inputs. The long-term goal in Dr Seth Berkley’s (CEO at Gavi, the Vaccine Alliance) vision is for COVAX to expand local production capacity through novel efforts, such as a mRNA vaccine technology, particularly in LMICs.

The need to improve vaccine manufacturing capacity in LMICs is strongly echoed in the recent reports “COVID-19: Make it the Last Pandemic”, published by the Independent Panel for Pandemic Preparedness and Response and “Responding to COVID-19 In Africa” released by PERC, which further cemented the urgency required from the global community to increase vaccine production and share technological expertise to facilitate local vaccine manufacturing, particularly in Africa, and other LMICs.

Ziccum is looking forward to engaging with the global community on these critical matters. In particular, it is essential that all the capabilities of the global vaccine community are leveraged —from vaccine R&D stakeholders through to those working in the clinical development, manufacturing, and regulatory sectors—to address short-term, medium-term, and long-term COVID-19 vaccine manufacturing challenges and bottlenecks.
To address the repeated calls for increased local vaccine production, Ziccum offers its novel ambient air-drying method.

Ziccum is currently planning to develop a series of aseptic modular Fill and Finish plants enabling individual countries to produce up to 30 million vials of thermostable dry-powder vaccines using Ziccum’s patented LaminarPace air-drying technology. This would equate to 300 million doses. Ziccum’s Fill and Finish plants will drive self-sufficiency and security of vaccine supplies across the globe to enable countries to better respond to COVID-19, prepare for inevitable future pandemics and continue routine immunization.

Ziccum CEO Göran Conradson: “We’re pleased to see this strong consensus emerging around the need for increased regional manufacturing of vaccines. As WHO Director General Dr Tedros recently said “the pandemic won’t be over anywhere until it’s over everywhere”.

“We need to manufacture more vaccines where they are needed most – formulated in the best possible way for that region. And we have the technology to do that! When a continent the size of Africa still has to rely on imports for 99% of its vaccine supply – even in the grip of a global pandemic – then we know the system needs improving. And pandemics are speeding up. The next may be right around the corner. The clock is ticking. Now is the time for innovation in vaccine formulation. We need to set vaccines free so that everyone can access, manufacture and formulate them in the best possible way for their people. There’s no time to waste. It’s time to work together.”

Links:

COVAX Manufacturing Task Force – More information available here [https://cepi.net/news_cepi/covax-manufacturing-task-force/]

The Independent Panel for Pandemic Preparedness and Response – “Covd-19: Make it the last Pandemic” [https://theindependentpanel.org/wp-content/uploads/2021/05/COVID-19-Make-it-the-Last-Pandemic_final.pdf]

Partnerships for Evidence-Based Response to COVID-19 (PERC) – “Responding to COVID-19 in Africa” [https://preventepidemics.org/wp-content/uploads/2021/05/PERC-Finding-the-Balance-Part-III-12-May-2021.pdf]

ZICCUM AB welcomes urgent calls to ramp up vaccine manufacturing across the globe to address inequity in vaccine access and prevent future pandemics

Ziccums incitamensprogram fulltecknade

Den 27 april 2021 beslutade årsstämman i Ziccum AB (publ) (”Ziccum” eller ”Bolaget”), efter förslag från styrelsen respektive valberedningen, att anta ett långsiktigt incitamentsprogram för styrelseledamöter i Bolaget bestående av teckningsoptioner, respektive ett långsiktigt incitamentsprogram för medarbetare i Bolaget bestående av personaloptioner.

Samtliga ledamöter i styrelsen respektive befintliga medarbetare har nu tecknat sig fullt ut i incitamentsprogrammen, innebärande att sammanlagt 46 000 teckningsoptioner kommer att emitteras till styrelseledamöterna i Bolaget och 42 456 personaloptioner att ges ut till medarbetare.

Lösenkursen i Styrelsens incitamentsprogram uppgår till 28,8 kr per aktie med en lösenperiod som pågår 1-31 maj 2024.

”Det är glädjande att se att såväl styrelsen som medarbetarna deltar i Ziccums incitamentsprogram, vilket tyder på en tro på bolaget och att deltagarna önskar bli aktieägare på sikt. Deltagandet stärker motivationen, ökar förutsättningarna för att behålla kompetens i Ziccum och borgar för ett maximerat värdeskapande för samtliga aktieägare”, kommenterar Fredrik Sjövall, styrelsens ordförande.

För mer information om Ziccum, vänligen kontakta:

Göran Conradson: VD Ziccum AB
E-post: conradson@ziccum.com
Mobil: 0709 61 55 99

Certified Adviser
Erik Penser Bank AB
E-post: certifiedadviser@penser.se
Telefon: 08 463 83 00

Om Ziccum

Ziccum utvecklar nya temperaturstabila versioner av världens mest behövda och livsavgörande vacciner. Med Bolagets patenterade teknologi LaminarPace möjliggörs produktion av nya, skonsamt torkade formuleringar som kan transporteras enkelt och kostnadseffektivt, utan krav på en komplicerad och dyr kylkedja hela vägen från fabrik till sista barnet längst bort från moderna logistiknoder.

Ziccums incitamensprogram fulltecknade

Ziccum AB: ‘Thermostable dry powder vaccines can play a key role in six UN Sustainable Development Goals’ – CFO

Ziccum AB is now integrating the UN’s Sustainable Development Goals (SDGs) into every aspect of its industrial and business strategy. CFO Frida Hjelmberg: “We have identified that our regional Fill and Finish plants formulating thermostable dry powder vaccines needing no Cold Chain could be a major engine for six key SDGs. The cost of rolling out such a new approach might seem high–but with the global economy standing to lose up to 9.2 trillion USD if we fail to ensure access to COVID-19 vaccines for LMI (low and middle income) economies, this makes great financial sense.”

“We have now placed sustainability at the heart of our strategic, business and operational focus” says Ziccum CFO Frida Hjelmberg. “Our commitment covers everything from our fast-moving product development work as we develop LaminarPace for industrial scale-up and GMP certification from the EMA – to the strategic collaborations we are working to progress with the UN, UNICEF, WHO, CEPI and more. We agree with GAVI that increased immunization is important in helping achieve almost all 17 of the UN’s Sustainable Development Goals, and we have identified six SDGs in particular that we believe our technology can play a significant role in.”

Breaking the vicious Cold Chain cycle

Ziccum aims to develop a series of Fill and Finish vaccine formulation plants worldwide, beginning in Sweden, built around its LaminarPace ambient air-drying system. Each plant would enable the local production of up to 30 million vials of thermostable dry powder vaccine, yielding up to 300 million doses. All could be transported in any climate, with no refrigerated Cold Chain. Significant reduction in carbon emissions in vaccine supply would directly help reduce many of the most important factors triggering pandemics Hjelmberg points out:

“Imbalances in the ecosystem, increased deforestation, habitat and species loss – all these directly fuel new pandemics” she says, “and yet the global Cold Chain we currently use to ship vaccines to treat these pandemics in itself is vast carbon-intense and thereby fuels more climate damage – in turn fueling more pandemics. It’s a vicious Cold Chain circle. Locally produced thermostable vaccines needing no Cold Chain would help remove vaccines from this vicious cycle. Economically it would be win-win-win-win, driving positive climate action, vaccine coverage and a sustainable development in LMI countries.”

The cost of unequal vaccine distribution

Hjelmberg argues strongly that regional vaccine manufacture and supply is crucial for global financial stability and prosperity. “According to studies (1) the global economy stands to lose as much as 9.2 trillion USD if the world fails to ensure access to COVID-19 vaccines for LMI economies” she says. “A global supply system that means some parts of the world get access to vaccines, but others don’t not only cause deaths – it spawns new virus mutations and leads to economic devastation. A new mechanism and new innovation is needed to ensure effective and sustainable ways to deploy vaccine access around the globe. Equal vaccine distribution will also minimize domestic economic damage due to interruptions in trading with unvaccinated regions. Ironically, significant parts of the economic cost in the absence of global vaccine coverage will be borne by the advanced economies, even if they manage to vaccinate their own citizens.”

Hjelmberg is optimistic about the growing agreement amongst vaccine players that new innovations and solutions for vaccine supply are urgently needed: “The cost of rolling out regional production and distribution of COVID-19 vaccines might seem high but it will be far cheaper than suffering the long-term economic effects of the pandemic. As John WH Denton, ICC Secretary General said – ‘This is not an act of charity – this is economic common sense’.

“By working together and innovating boldly we can defeat Covid-19 and improve vaccine coverage, climate action and sustainable development. Removing vaccines from the vicious cold chain cycle of global carbon-intensive supply chains could create a new virtuous cycle of sustainable growth and development, with vaccines at its heart.”

Read about Ziccum’s 6 target SDGs here

(1) https://iccwbo.org/publication/the-economic-case-for-global-vaccinations/

Ziccum AB: ‘Thermostable dry powder vaccines can play a key role in six UN Sustainable Development Goals’ – CFO

Kommuniké från årsstämma i Ziccum AB (publ)

Ziccum AB (publ) (”Ziccum”) avhöll den 27 april 2021 årsstämma. Med anledning av rådande covid-19-pandemi hölls årsstämman endast genom poströstning. Vid stämman fattades bland annat följande beslut.

Fastställande av årsbokslut och ansvarsfrihet
Stämman beslutade att fastställa resultat- och balansräkning för Ziccum för räkenskapsåret 2020. Stämman beslutade även om ansvarsfrihet för styrelseledamöterna och verkställande direktören för deras förvaltning av bolagets angelägenheter under räkenskapsåret 2020.

Resultatdisposition
Stämman beslutade, i enlighet med styrelsens förslag, att Ziccums resultat ska balanseras i ny räkning, och att någon utdelning således inte lämnas.

Styrelse och revisor
Stämman beslutade, i enlighet med valberedningens förslag, om omval av Fredrik Sjövall, Mikaela Bruhammar, Kristian Kierkegaard och Mattias Münnich samt att val av Andreas Pettersson Rohman som styrelseledamöter. Fredrik Sjövall omvaldes även till styrelseordförande. Till revisor omvaldes vidare revisionsbolaget Ernst & Young Aktiebolag.

Stämman beslutade vidare om styrelsearvode i enlighet med valberedningens förslag. Stämman beslutade även, i enlighet med valberedningens förslag, att revisorsarvode ska utgå enligt godkänd räkning.

Emissionsbemyndigande
Stämman beslutade, i enlighet med styrelsen förslag, att bemyndiga styrelsen att, vid ett eller flera tillfällen fram till nästa årsstämma besluta om att öka bolagets aktiekapital genom nyemission av aktier, teckningsoptioner eller konvertibler. Sådant emissionsbeslut ska kunna fatttas med eller utan avvikelse från aktieägarnas företrädesrätt samt med eller utan bestämmelse om apport eller kvittning eller andra villkor. Antalet aktier som ska kunna ges ut, eller, vid emission av konvertibler eller teckningsoptioner, tillkomma efter konvertering eller utnyttjande, med stöd av bemyndigandet ska vara begränsat till 30 procent av dagens antal utestående aktier.

Syftet med bemyndigandet är att öka bolagets finansiella flexibilitet och styrelsens handlingsutrymme. Om styrelsen beslutar om emission utan företrädesrätt för aktieägarna så ska skälet vara att kunna bredda ägarkretsen, anskaffa eller möjliggöra anskaffning av rörelsekapital, öka likviditeten i aktien, genomföra företagsförvärv eller anskaffa eller möjliggöra anskaffning av kapital för företagsförvärv.

Ändring av bolagsordningen
Stämman beslutade, i enlighet med styrelsens förslag, att ändra bolagsordningen.

Incitamentsprogram
Stämman beslutade, i enlighet med styrelsens förslag, att anta ett incitamentsprogram till vissa anställda och konsulter i form av personaloptioner. Incitamentsprogrammet innebär i korthet en emission av högst 46 000 personaloptioner. Stämman beslutade vidare att emittera högst 60 454 teckningsoptioner för att säkra leverans av aktier till deltagare och för att säkra kostnader förknippade med programmet. Varje personaloption ger rätt att teckna en ny aktie i Ziccum under tiden från och med den 1 maj 2024 till och med den 31 maj 2024.

Stämman beslutade därutöver, i enlighet med valberedningens förslag, att anta ett incitamentsprogram till styrelseledamöter i form av teckningsoptioner. Incitamentsprogrammet innebär i korthet en emission av högst 46 000 teckningsoptioner. Varje teckningsoption ger rätt att teckna en ny aktie i Ziccum under tiden från och med den 1 maj 2024 till och med den 31 maj 2024.

Kommuniké från årsstämma i Ziccum AB (publ)

1 2 3 … 18 19 20 21 22 23 24 … 31 32 33

Posts navigation